miRNA Expression Composition for Complement and Factor Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dysregulated expression of bioactive molecules such as complements and factors leads to homeostatic imbalance, resulting in disease, and existing therapies are inadequate for effectively regulating their production.
Innovation Solution
Compositions comprising recombinant plasmids encoding miRNA sequences that target and degrade the mRNA of specific biomolecules like complements and factors, administered via vectors like adeno-associated virus, to upregulate miRNA production and decrease the expression of these molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to regulate bioactive molecule production, then some regulation is achieved, but the regulation is inadequate and homeostatic imbalance persists
Solution Approach 1:
The patent introduces miRNA as an intermediary molecule that mediates the regulation of bioactive molecules. The recombinant plasmid encodes miRNA sequences that specifically target and degrade mRNA of complement and factor molecules, providing a precise and effective regulatory mechanism that overcomes the inadequacy of existing therapies while maintaining biological system compatibility
2Reliability
If miRNA production is upregulated to decrease target biomolecule expression, then homeostasis is restored, but the mechanism requires recombinant plasmid administration
Solution Approach 1:
The recombinant plasmid is designed to be self-replicating and self-expressing within host cells. Once administered, the plasmid autonomously replicates and expresses miRNA sequences, eliminating the need for continuous external administration and enabling sustained homeostatic regulation of bioactive molecules
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively downregulate the production of target biomolecules, restoring homeostasis and potentially treating associated diseases by increasing miRNA production within cells.
Implementation Method 1
the miRNA can cause the target mRNA to be degraded or inactivated
Implementation Method 2
administered via vectors like adeno-associated virus, to upregulate miRNA production
Data Source
AI summary
Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a complement or a factor. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C1q, complement C1r, complement C1s, complement C3 or complement C5. In some embodiments of the present disclosure, the target biomolecule is a factor such as Factor B, Factor D or Factor 10.